<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01293058</url>
  </required_header>
  <id_info>
    <org_study_id>ASD-1213-16</org_study_id>
    <nct_id>NCT01293058</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Intranasal Versus Intravenous Naloxone in Level of Consciousness in Suspected Opioid Overdose</brief_title>
  <official_title>Study of Routs of Naloxone Administration for Opioid Overdosed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Isfahan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Isfahan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which route of administration is better for
      treatment of opioid overdosed patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In intravenous drug abusers (IDUs), as a result of previous intravenous substance abuse, the
      predictable difficult cannulate exist and cause the delay administration of antidote therapy.
      Additionally, IDUs are also at increased risk of carrying blood borne infections that could
      be transmitted to healthcare workers through needle stick injuries. The investigators aimed
      to compare intranasal administration of naloxone with intravenous route.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>level of consciousness</measure>
    <time_frame>4 min after naloxone administration</time_frame>
    <description>The investigators evaluated the level of consciousness with Glasgow coma sclae 4 minutes after naloxone administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>at 4 min after naloxone administration</time_frame>
    <description>The investigators evaluated blood pressure 4 minutes after naloxone administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Morphinan Opioid Overdose</condition>
  <arm_group>
    <arm_group_label>Intravenous</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The investigators administered intravenous naloxone for our opioid overdose patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The investigators administered intranasal naloxone for treatment of our patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intranasal naloxone</intervention_name>
    <description>spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness</description>
    <arm_group_label>Intranasal</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous</intervention_name>
    <description>Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness</description>
    <arm_group_label>Intravenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the range of 15-50 years old

               -  Who were suspicious to opioid overdoses based on history and having clinical
                  appearance such as miotic pupils with loss of consciousness

               -  Give response to naloxone with increasing the level of consciousness

        Exclusion Criteria:

          -  Not giving response to naloxone and suspicious to have another reason for loss of
             consciousness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nastaran Izadi, A.Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isfahan University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Noor university hospital</name>
      <address>
        <city>Isfahan</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <link>
    <url>http://mui.ac.ir</url>
    <description>Isfahan university of medical sciences</description>
  </link>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2011</study_first_submitted>
  <study_first_submitted_qc>February 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2011</study_first_posted>
  <last_update_submitted>February 9, 2011</last_update_submitted>
  <last_update_submitted_qc>February 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Alireza Yousefy, Associate Professor of Medical Education</name_title>
    <organization>Isfahan University of Medical Sciences</organization>
  </responsible_party>
  <keyword>opioid</keyword>
  <keyword>overdose</keyword>
  <keyword>naloxone</keyword>
  <keyword>intranasal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug Overdose</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

